Atlas Venture Life Science Advisors LLC Buys New Position in ImageneBio, Inc. $IMA

Atlas Venture Life Science Advisors LLC bought a new position in shares of ImageneBio, Inc. (NASDAQ:IMA) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 377,814 shares of the company’s stock, valued at approximately $3,079,000. ImageneBio makes up about 0.4% of Atlas Venture Life Science Advisors LLC’s holdings, making the stock its 9th biggest holding. Atlas Venture Life Science Advisors LLC owned 9.43% of ImageneBio as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently made changes to their positions in IMA. Goldman Sachs Group Inc. lifted its position in shares of ImageneBio by 62.4% during the first quarter. Goldman Sachs Group Inc. now owns 76,464 shares of the company’s stock worth $98,000 after acquiring an additional 29,369 shares in the last quarter. Aldebaran Capital LLC purchased a new position in ImageneBio during the 3rd quarter valued at about $159,000. BML Capital Management LLC bought a new stake in shares of ImageneBio during the third quarter valued at about $1,487,000. Vanguard Group Inc. bought a new stake in shares of ImageneBio during the third quarter valued at about $1,902,000. Finally, Blue Owl Capital Holdings LP purchased a new stake in shares of ImageneBio in the third quarter worth about $4,409,000. 75.00% of the stock is currently owned by institutional investors.

ImageneBio Stock Performance

Shares of ImageneBio stock opened at $5.91 on Friday. The company has a market capitalization of $66.07 million, a PE ratio of -0.73 and a beta of 0.44. ImageneBio, Inc. has a one year low of $5.70 and a one year high of $18.00. The company has a 50-day simple moving average of $6.72 and a two-hundred day simple moving average of $7.58.

ImageneBio (NASDAQ:IMA) last issued its quarterly earnings results on Tuesday, March 10th. The company reported $0.34 earnings per share (EPS) for the quarter. On average, equities analysts predict that ImageneBio, Inc. will post -0.91 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have issued reports on IMA. Wedbush cut shares of ImageneBio from a “neutral” rating to an “underperform” rating in a research note on Tuesday, November 25th. Wall Street Zen upgraded ImageneBio from a “strong sell” rating to a “hold” rating in a research report on Saturday. One research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, ImageneBio has a consensus rating of “Hold” and a consensus price target of $26.50.

Insider Buying and Selling at ImageneBio

In related news, Director Joseph P. Slattery bought 16,000 shares of the firm’s stock in a transaction that occurred on Wednesday, December 24th. The stock was purchased at an average cost of $5.99 per share, for a total transaction of $95,840.00. Following the completion of the acquisition, the director owned 16,000 shares in the company, valued at approximately $95,840. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 5.94% of the company’s stock.

About ImageneBio

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025. ImageneBio, Inc is headquartered in San Diego, California.